NeuroPace (NPCE) Scheduled to Post Quarterly Earnings on Wednesday

NeuroPace (NASDAQ:NPCE) is scheduled to release its earnings data after the market closes on Wednesday, May 8th. Analysts expect NeuroPace to post earnings of ($0.32) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.10. NeuroPace had a negative return on equity of 153.76% and a negative net margin of 50.38%. The business had revenue of $18.01 million for the quarter, compared to analyst estimates of $17.74 million. On average, analysts expect NeuroPace to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NeuroPace Trading Down 1.2 %

NASDAQ:NPCE opened at $13.47 on Tuesday. The company has a market cap of $386.86 million, a P/E ratio of -10.52 and a beta of 2.06. NeuroPace has a twelve month low of $3.80 and a twelve month high of $18.15. The business has a 50 day moving average price of $13.98 and a two-hundred day moving average price of $11.92. The company has a quick ratio of 5.02, a current ratio of 5.71 and a debt-to-equity ratio of 2.76.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of NeuroPace in a research report on Tuesday, January 30th. Morgan Stanley raised their price objective on NeuroPace from $9.00 to $13.00 and gave the company an “equal weight” rating in a report on Wednesday, March 6th. Wells Fargo & Company upgraded NeuroPace from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $16.00 to $20.00 in a report on Thursday, March 14th. SVB Leerink started coverage on NeuroPace in a research note on Tuesday, January 30th. They issued an “outperform” rating and a $22.00 price target for the company. Finally, Cantor Fitzgerald upped their price objective on NeuroPace from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $15.67.

Insider Activity

In related news, major shareholder Orbimed Advisors Llc sold 461,899 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $14.49, for a total transaction of $6,692,916.51. Following the transaction, the insider now directly owns 3,542,068 shares of the company’s stock, valued at approximately $51,324,565.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 525,345 shares of company stock valued at $7,583,250 over the last three months. Insiders own 27.50% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.